The University of Nottingham spin-out company Oncimmune pioneers anti-cancer technology, and has reached the final stages of its research which could identify an immune response to breast cancer.
The initial research came out of the laboratories of cancer specialist, John Robertson, Professor of Surgery at The University of Nottingham. If this test can be developed it will be the first of its kind in the world and it could be on trial in America this year.
Professor Robertson and his team need at least 3,500 healthy people to come forward and donate a blood sample which would be used both for further research and to help develop the technology. The researchers emphasise that there will not be any feedback of results to the donor.
Professor Robertson said: “We are getting close to having a blood test that will provide a better chance of identifying more people who have an early stage breast cancer at a point when it can be cured.”
This huge blood collection project begins in earnest this month with a team of medical and support staff initially using health centres in their search for volunteers aged anywhere between 18 and 90 — to cover all decades of life. The team is also planning to take to the road travelling, by bus, to supermarkets, town centre markets, farmer’s markets, health centres and libraries.
The search for donors starts in Nottinghamshire and move to Derbyshire and Leicestershire over the coming months.
Oncimmune's tests for cancer measure auto-antibodies that accumulate in the blood in reaction to the presence of a cancerous tumour, even when the tumour is in its earliest stages. Preliminary studies have already shown that the test can be positive up to four years earlier than a mammogram might indicate a breast cancer.
A £150,000 donation from Nottingham University Hospitals Charity has helped Oncimmune invest in state of the art robot equipment to speed up part of the testing process. Some of the money was raised through the auction of an abstract work of art by Jennie Bambury which featured breast imprints of Nottinghamshire celebrities.
Most families have been affected by cancer and the best way to cure cancer is to detect it before it spreads. The difficulty is that a number of cancers, such as breast, colorectal, prostate and ovarian cancer, will have spread in the majority of patients before they are diagnosed.
Research into the detection of the immune response to breast and other types of cancer continues in Professor Robertson’s laboratories at The University of Nottingham while the development of commercial products is funded through Oncimmune, Ltd.
In November last year Oncimmune announced the company was to open a North American arm in a 30 million dollar deal that also involved collaboration with cancer researchers at the University of Kansas.
Emma Thorne | alfa
Speed data for the brain’s navigation system
06.12.2016 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)
Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
06.12.2016 | Materials Sciences
06.12.2016 | Medical Engineering
06.12.2016 | Power and Electrical Engineering